详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

L. Zhang[1] ; Y. Huang[1] ; Y. Yang[1] ; S.Ma[1] ; X. Lin[2] ; L. Lin[3] ; T. Zhou[4] ; Y. Deng[5] ; C. Zhang[6] ; X. Ding[7] ; S. Wang[8] ; R. Wang[9] ; G. Feng[10] ; Y. Chen[11] ; R. Xu[12] ;

机构： [1]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, [2]Medical Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, [3]Oncology, The First Affiliated Hospital of Guangdong University of Traditional Chinese Medicine, Guangzhou, China, [4]Radiation Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, China, [5]Oncology, Foshan FirstPeople Hospital, Foshan, China, [6]Radiation Oncology, Dongguan People Hospital, Dongguan, China, [7]Medical Oncology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China, [8]Oncology, Peking University Shenzhen Hospital, Shenzhen, China, [9]Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China, [10]Oncology, The People’s Hospital of Guangxi Zhuang Autonomous Region, Guangxi, China, [11]Medical Oncology, Hainan General Hospital, Hainan Clinical Medicine Research Institution, Hainan, China, [12]Medical Oncology, Shenzhen People’s Hospital, Second Clinical Medical College of Jinan University, Shenzhen, China

出处：

ISSN：

语种：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

第一作者：

第一作者机构： [1]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China,

推荐引用方式(GB/T 7714)：

APA：

MLA：

First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial

文献详情